Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk ... Jon Wertheim: So your next building needs to be the molecule of an anti-obesity drug.

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations, said that its net profit in the third quarter hit 27.3 billion Danish kroner, just above an LSEG ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs ...

LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an ...

Novo Nordisk on Wednesday nudged higher its profit outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs. Novo Nordisk said its third-quarter ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

LONDON — Sales of Novo Nordisk’s obesity drug Wegovy jumped in the third quarter, the company said Wednesday as it reported quarterly profits that were in line with analyst expectations.

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...